Pharmacokinetics of tacrolimus: clinically relevant aspects.
Undre
N A
NA
Fujisawa GmbH, Munich, Germany.
Stevenson
P
P
Schäfer
A
A
D003922:Diabetes Mellitus, Type 1 / Q000139:chemically induced; D004359:Drug Therapy, Combination; D005947:Glucose / Q000378:metabolism; D006084:Graft Rejection / Q000188:drug therapy / Q000517:prevention & control*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008657:Metabolic Clearance Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000493:pharmacokinetics* / Q000627:therapeutic use; D014202:Tremor / Q000139:chemically induced
D007166:Immunosuppressive Agents; D005947:Glucose; D016559:Tacrolimus